A5091008679- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Pharmacology and Obesity Treatment
- Hormonal Regulation and Hypertension
- Diet, Metabolism, and Disease
- Diet and metabolism studies
- Cardiovascular Health and Disease Prevention
- Pharmaceutical Economics and Policy
- Alcohol Consumption and Health Effects
- Gout, Hyperuricemia, Uric Acid
- Lipid metabolism and disorders
- Hepatitis C virus research
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Heart Rate Variability and Autonomic Control
- Chronic Kidney Disease and Diabetes
- Cerebrovascular and Carotid Artery Diseases
- Metabolism, Diabetes, and Cancer
- Cardiovascular Disease and Adiposity
- Antiplatelet Therapy and Cardiovascular Diseases
Aristotle University of Thessaloniki
2014-2023
Hippocration General Hospital
2012-2021
Ippokrateio General Hospital of Thessaloniki
2016-2019
University of Dundee
2018
NYU Langone Health
2018
University College London
2004-2017
University of Córdoba
2017
Biotechnology Research Center
2017
Mashhad University of Medical Sciences
2017
Victor Babeș University of Medicine and Pharmacy Timișoara
2017
SummaryBackground: Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there no long-term survival study that evaluated this statin.Patients−Methods: To assess the effect of atorvastatin on morbidity and mortality (total coronary) patients with established coronary heart disease (CHD), 1600 consecutive were randomised either to or 'usual' medical care. The dose was titrated from 10 80mg/day, order reach National Cholesterol Education...
Background: Little is known about statins in the prevention of dyslipidaemia induced renal function decline. The secondary coronary heart disease (CHD) GREACE study suggested that dose titration with atorvastatin (10–80 mg/day, mean 24 mg/day) achieves national cholesterol educational programme treatment goals and significantly reduces morbidity mortality, compared usual care. Aims: To report effect statin on untreated both groups. Methods/Results: All patients had plasma creatinine values...
a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where pathophysiology, diagnosis management were comprehensively presented.
OBJECTIVE—This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND METHODS—A total 120 consecutive patients, who were free coronary artery disease (CAD) at entry, studied for period 24 weeks. These randomly assigned atorvastatin (20 mg/day, n = 40), micronized fenofibrate (200 or both (atorvastatin 20 mg/day plus 200 40). The treatment LDL...
ABSTRACTBackground: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (MetS). There no established treatment for NAFLD.Aim: To evaluate a multifactorial intervention in NAFLD.Methods: A prospective, open-label, randomised study non-diabetic patients (n = 186) with MetS (follow-up: 54 weeks). All had both biochemical and ultrasonographic evidence NAFLD at baseline. Other causes were excluded. Patients received lifestyle advice hypertension (mainly...
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on pathophysiology, atherogenicity clinical significance low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses measurement issues, while II focused effects drug lifestyle modifications. Suggestions for future research field are highlighted at end II. Each includes Conclusions.
Objective: The prevalence of metabolic syndrome (MetS), using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF) definitions, was compared in 9669 subjects, representing Greek population.Results: age-adjusted NCEP III-defined MetS 24.5% whereas that IDF-defined 43.4% (+77%, p < 0.0001). majority (up to 69%) older age groups had MetS. calculated vascular event risk low (6.1% 7.2% Framingham PROCAM calculation,...
Metabolic syndrome (MetS) is associated with increased risk for both vascular and chronic kidney disease. Whether statins ameliorate these risks not established.This post hoc analysis of the GREek Atorvastatin Coronary heart disease (CHD). Evaluation (GREACE) examines effect on estimated glomerular filtration rate (e-GFR) serum uric acid (SUA) levels their relation to events in CHD patients MetS. MetS were divided into two groups: Group A (n = 365) received lifestyle advice, target-driven...
The purpose of this study was to investigate the relationship between alcohol consumption and prevalence metabolic syndrome (MetS), type 2 diabetes mellitus (DM), coronary heart disease (CHD), stroke, peripheral arterial (PAD), overall cardiovascular (CVD) in a Mediterranean cohort. It consisted cross-sectional analysis representative sample Greek adults (n = 4153) classified as never, occasional, mild, moderate, or heavy drinkers. Cases with overt CHD, PAD were recorded. In our population,...
Statins are one of the most commonly prescribed drugs in clinical practice. They usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy muscle-related. The recent statement European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), avoided use term 'statin intolerance'. Although syndromes common observed after therapy, excluding other side might underestimate number patients intolerance,...